Respirics
  • Home
  • About Us
  • I-Point
  • Products
  • Partnership
  • Publications
  • Press
  • Contact
  • Nanotherapeutics Awarded $20 Million NIAID/BARDA Contract to Develop Inhaled Gentamicin for Treatment of Aerosol Exposure to Bioterrorism Agents
  • Respirics to Divest Device Assets
  • Respirics Announces Launch of MD Turbo
  • Accentia Biopharmaceuticals to Begin Shipping MD Turbo
  • Respirics Inc. Completed Series A Financing
  • Respirics Inc. Receives 510(k) Clearance for its MD Turbo Device For Use with Metered Dose Inhalers
  • TEAMM Pharmaceuticals, Inc. and Respirics, Inc. Announce Development And Licensing Deal
  • Companies Plan Better Inhaler

Press Releases

October 11, 2007
Alachua, Florida

Nanotherapeutics Awarded $20 Million NIAIS/BARDA Contract to Develop Inhaled Gentamicin for Treatment of Aerosol Exposure to Bioterrorism Agents

June 13, 2007
Raleigh, North Carolina

Respirics to Divest MD Turbo

June 14, 2006
Raleigh, North Carolina

Respirics Announces Launch of MD Turbo

April 11, 2006
Tampa, Florida

Accentia Biopharmaceuticals to Begin Shipping MD Turbo

September 27, 2005
Raleigh, North Carolina

Respirics Inc. Completed Series A Financing

August 16, 2005
Raleigh, North Carolina

Respirics Inc. Receives 510(k) Clearance for its MD Turbo Device For Use with Metered Dose Inhalers

January 28, 2003
Morrisville, N.C.

TEAMM Pharmaceuticals, Inc. and Respirics, Inc. Announce Development And Licensing Deal

January 28, 2003
Morrisville, North Carolina

Companies Plan Better Inhaler By David Ranii, NewsObserver.com, Staff Writer

news and events

© 2005 Respirics. All Rights Reserved. Web site design by CrossComm